Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) causes fourth leading cancer death in the United States in year 2014 \[[@b1-crt-2016-336]\]. Although only 10% to 20% has chance of resection, it is the only treatment that promises curing the disease \[[@b2-crt-2016-336]\]. Regarding the margin status after pancreaticoduodenectomy (PD) for PDAC, controversy exists about the impact of microscopic resection margin involvement (R1). Several studies have reported that it is an independent prognostic factor for poor long term survival \[[@b3-crt-2016-336]-[@b6-crt-2016-336]\], but not in other studies \[[@b7-crt-2016-336],[@b8-crt-2016-336]\]. Main reason of this controversy partly originated from the issues of standardization of pathologic examination \[[@b9-crt-2016-336],[@b10-crt-2016-336]\]. The standardization of pathological examination increased the rate of R1 resections after PD from 20% to 50% \[[@b11-crt-2016-336]-[@b13-crt-2016-336]\], and even to \> 70% \[[@b14-crt-2016-336]-[@b17-crt-2016-336]\]. Moreover, there is ongoing debate concerning the definition of R1. According to the International Union Against Cancer (UICC) and the College of American Pathologists (CAP) reporting guidelines, R1 is defined as the microscopic presence of tumor cells at definite resection margin \[[@b18-crt-2016-336],[@b19-crt-2016-336]\]. However, the Royal College of Pathologists (RCP) in the UK recommends that cases with microscopic evidence of tumor extension to within 1 mm from a circumferential margin or surface of the pancreatic resection specimen should be classified as R1 \[[@b20-crt-2016-336]\].

Accurate assessment of R1 is clinically important, not only because it provides prognostic information but stratification within the setting of randomized controlled trials of adjuvant therapy is based partly upon margin positivity. Appropriate identification of those patients who would most benefit is critical in the improvement of the management for PDAC.

Here, we conducted a systematic review and meta-analysis to assess the impact of resection margin distance on the survival of the patients with PDAC. We intended to identify survival outcomes with different margin status: involved margin (R0 mm), margin clearance with ≤ 1 mm (R0-1 mm), and margin with \> 1 mm (R\>1 mm).

Materials and Methods
=====================

1. Data sources and search strategy
-----------------------------------

We performed a systematic literature review of published articles and unpublished abstracts, which reported overall survival of the patients with different surgical margin distance after resection of pancreatic cancer. Comprehensive searches were performed in the databases of PubMed, EMBASE, and Cochrane Library (last search update on 6 April 2015). The following key words with their corresponding MeSH terms were used: combined to maximize sensitivity: \[(pancreatic cancer)\[MESH\] OR (pancrea^\*^ AND cancer) OR (pancrea^\*^ AND adenocarcinoma)\]\[All Fields\] AND \[margin\]\[TIAB\]. Additionally, the references cited in retrieved articles were scrutinized by manual search.

2. Study selection
------------------

Two authors (K.S.K. and K.K.) independently reviewed search results. Inclusion criteria were observational studies that investigated survival outcomes according to different resection margin distance following PD for PDAC: involved margin (R0 mm), margin clearance with ≤ 1 mm (R0-1 mm), and margin with \> 1 mm (R\>1 mm). To limit heterogeneity across the studies and to get more clinically meaningful results, we used following exclusion criteria: (1) studies that included pancreatic malignancy other than adenocarcinoma, (2) review articles or case reports, (3) studies that did not report surgical margin status, and (4) studies that did not provide sufficient data to acquire hazard ratio (HR) and its 95% confidence interval (CI) of different margin status for overall survival (OS). Manual search for references of the eligible studies was performed to minimize potential missing data.

3. Data extraction
------------------

Data were extracted independently by two authors (K.S.K. and K.K.), and discrepancies were resolved by consensus. The following details were extracted: name of first author, institution, country, study period, publication year, number of participants, surgery type, T stage, N stage, adjuvant treatment details, follow-up period, and pathologic examination protocol.

4. Risk of bias assessment
--------------------------

Risk of bias was assessed by Risk of Bias Assessment tool for Non-randomized Studies (RoBANS), which was validated for assessing the risk of bias for nonrandomized studies \[[@b21-crt-2016-336]\]. It contains six domains: selection of participants, confounding variables, intervention measurement, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. Two authors (K.S.K. and K.K.) independently assessed and disagreements were resolved by consensus.

5. Statistical analysis
-----------------------

The OS outcome was measured in terms of the time-to-event HR of R0 mm compared with R0-1 mm and R0-1 mm with R\>1 mm. HR as well as its 95% CI was directly extracted from the text or estimated using the published Kaplan-Meier curves using the methods of Tierney et al. \[[@b22-crt-2016-336]\]. Pooled HR was calculated using the random-effects model and presented with forest plots. Two-sided p-values less than 0.05 were considered statistically significant. A chi-square statistic was used to test for statistical heterogeneity, and I^2^ statistic was also calculated to evaluate the extent of variability attributable to statistical heterogeneity between trials. To assess the publication bias, we applied funnel plot method together with the Egger's regression test. All statistical analysis was done using RevMan 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark).

Results
=======

1. Selecting studies and characteristics of included studies
------------------------------------------------------------

Two thousand eight hundred ninety-four studies were obtained from the searches of electronic database using our searching strategy. A total of 106 articles were reviewed in detail. Eight studies were finally selected into this meta-analysis \[[@b16-crt-2016-336],[@b17-crt-2016-336],[@b23-crt-2016-336]-[@b28-crt-2016-336]\]. All of studies were retrospective observational cohort studies reporting survival outcome of resected pancreatic cancer at single center. Two studies were presented in abstract form only \[[@b25-crt-2016-336],[@b28-crt-2016-336]\]. The details of study selection are shown in [Fig. 1](#f1-crt-2016-336){ref-type="fig"}. Two studies were reported from Unites States, two studies from UK, two studies from Japan, one study from Germany, and one study from Australia. The patients with R0 mm or R0-1 mm constitute 27.4% to 78.5%. Regarding surgical treatments, most of the patients underwent PD. In three studies, patients treated with distal pancreatectomy were included with the proportion of 19%, 15.3%, and 20.2%, respectively \[[@b23-crt-2016-336],[@b26-crt-2016-336],[@b27-crt-2016-336]\]. Only two studies described the proportion of the T and N stage according to the resection margin status \[[@b26-crt-2016-336],[@b27-crt-2016-336]\]. In four studies, the percentage of the patients treated with adjuvant or neoadjuvant therapy was described. Basic characteristics of included studies are shown in [Table 1](#t1-crt-2016-336){ref-type="table"}. Details of pathologic evaluation of margin status are listed in [Table 2](#t2-crt-2016-336){ref-type="table"}. Details of pathologic examination protocol were described in six studies \[[@b14-crt-2016-336],[@b20-crt-2016-336],[@b29-crt-2016-336]\]. A summary of the risk of bias assessment is provided in [Table 3](#t3-crt-2016-336){ref-type="table"}.

2. Impact of resection margin distance on survival
--------------------------------------------------

We calculated overall pooled HR for OS with a random effects model. Chang et al. \[[@b23-crt-2016-336]\] reported disease-specific survival (DSS) instead of OS. Under the assumption that the DSS outcome might not differ from the OS, we pooled these data with the OS outcomes of the other seven studies. When we compared R\>1 mm and R0-1 mm, R\>1 mm had reduced risk of death than R0-1 mm (HR, 0.74; 95% CI, 0.61 to 0.88; p=0.001) ([Fig. 2A](#f2-crt-2016-336){ref-type="fig"}). There was no heterogeneity between the included studies (I^2^ index=42%, p=0.10). When we compared R0 mm with R0-1 mm, R0-1 mm had reduced risk of death (HR, 0.81; 95% CI, 0.72 to 0.91; p \< 0.001) ([Fig. 2B](#f2-crt-2016-336){ref-type="fig"}). There was no heterogeneity among studies (I^2^ index=0%, p=0.82).

3. Publication bias
-------------------

A funnel plot of the effect size for each subgroup category of the trial against the precision showed no asymmetry ([Fig. 3](#f3-crt-2016-336){ref-type="fig"}). Egger's regression test for potential publication bias yielded no potential unpublished studies. (Egger's test, p=0.373 for between R\>1 mm and R0-1 mm, p=0.852 for between R0-1 mm and R0 mm, respectively).

Discussion
==========

The reported R1 rates after PD for PDAC showed a high variation ranging from 17% to 85%. Previous studies which reported low R1 resection rates of less than 20% had local recurrence rate of 60%-80% \[[@b7-crt-2016-336],[@b30-crt-2016-336],[@b31-crt-2016-336]\]. These findings indicated a considerable underestimation of the true R1 status. Lack of a standardized pathological examination protocol and different definitions of resection margin are probably the main reasons for the high variation in reported R1 rates. In this meta-analysis, six studies explained details of standardized pathological examination. Eventually, when '1 mm rule' was applied, R1 rates were greater than 35.6% except a study by Janot et al. \[[@b24-crt-2016-336]\] which had low number of patients.

Controversy exists over the anterior surface of PD specimens as to whether it should be regarded as part of the resection margin. Anterior surface as a resection margin was recommended in Japan \[[@b32-crt-2016-336],[@b33-crt-2016-336]\] and in Europe \[[@b14-crt-2016-336]\]. Because the surgeon does not transect any tissues in this area, however, anterior surface was not regarded a true resection mar gin. Some authors proposed that assessment of this margin should be excluded from a standardized pathological examination protocol \[[@b15-crt-2016-336]\], or that the "0 mm" clearance rule should be used \[[@b9-crt-2016-336],[@b34-crt-2016-336]\]. While most common involved margin in the pancreatic cancer is the medial or posterior resection margin \[[@b15-crt-2016-336]\], Jamieson et al. \[[@b35-crt-2016-336]\] reported that R1 at anterior surface made up 12.8% of the R1 cases and that these patients presented favorable outcome than those with R1 at medial or transection margin. In this meta-analysis, anterior surface was considered a resection margin in only two studies \[[@b17-crt-2016-336],[@b24-crt-2016-336]\].

The '1 mm rule' has been adopted from the association between the circumferential margin status and local recurrence of the rectal cancer. Verbeke et al. \[[@b36-crt-2016-336]\] reported that tumor growth in pancreatic head cancers is more dispersed than in rectal cancer, claiming that 1 mm definition needs to be considered. Single institutional studies including encompassed ones in this meta-analysis reported the association of the margin clearance with OS. Chang et al. \[[@b23-crt-2016-336]\] and Jamieson et al. \[[@b17-crt-2016-336]\] demonstrated that margin clearance by at least 1.5 mm identified a subgroup of patients which may potentially achieve long-term survival. Gebauer et al. \[[@b37-crt-2016-336]\] reported that margin clearance of 2 mm or greater as an independent prognostic factor for OS. However, because each study had limited number of patients, any conclusive result could not be drawn. Through the pooled HR of current meta-analysis including 1,932 patients, we could verify that R\>1 mm had reduced risk of death than R0-1 mm, and R0-1 mm also had reduced risk of death than R0 mm.

While adjuvant chemotherapy is currently the standard treatment for patients following a potentially curative PD for PDAC in Europe, chemoradiotherapy as an adjuvant treatment is considered based on the margin status. Two recent meta-analyses have suggested that patients with R1 status appear to benefit from postoperative chemoradiotherapy \[[@b8-crt-2016-336],[@b38-crt-2016-336]\]. Chang et al. \[[@b23-crt-2016-336]\] noted that patients with close resection margins (\< 1.5 mm) may have a better response to adjuvant radiotherapy compared with involved margins (R0 mm) as a result of the probable low volume of residual local disease, and potentially constitute a subgroup that is most likely to have the greatest benefit. In conjunction with these results, our results could be used in identifying a subgroup that will benefit from radiotherapy after PD for PDAC.

Several studies examined the effect of neoadjuvant treatment on resection margin status \[[@b7-crt-2016-336],[@b39-crt-2016-336]-[@b42-crt-2016-336]\]. Katz et al. \[[@b40-crt-2016-336]\] reported that patients who received chemoradiation had longer superior mesenteric artery margin distances than those who did not. In the study by Delpero et al. \[[@b42-crt-2016-336]\], neoadjuvant treatment was correlated with a reduced risk for a positive posterior margin. In contrary, Raut et al. \[[@b7-crt-2016-336]\] reported that neoadjuvant therapy was not a statistically significant predictor of margin status. In one study by Thomay et al. \[[@b25-crt-2016-336]\] included in this meta-analysis, neoadjuvant treatment was given to 34% of the patients. The patients with R0-1 mm had similar risk of death compared to R\>1 mm, and 34% reduction of death compared to R0 mm in that study. One might argue that high proportion of neoadjuvant treatment than other studies might explain the result. However, the hypothesis that neoadjuvant treatment could decrease the adverse effect of R1 is not evidenced by randomized trials. Further studies to investigate the role of neoadjuvant treatment using a standardized pathological examination protocol are warranted.

Major limitation of our study is that included studies did not provide adequate information on the distribution of prognostic factors according to margin status. Given that most of the patients were of T3-4 and/or lymph node involvement, stratification according to resection margin status could not be assessed except two studies \[[@b26-crt-2016-336],[@b27-crt-2016-336]\]. Moreover, except a study by Sugiura et al. \[[@b26-crt-2016-336]\] detailed proportion of the patients who received adjuvant or neoadjuvant therapy among the different resection margin could not be evaluated. In addition, two studies in this meta-analysis were reported in abstract form only \[[@b25-crt-2016-336],[@b28-crt-2016-336]\]. However, excluding these two studies did not alter the pooled result (for R\>1 mm and R0-1 mm: HR, 0.73; 95% CI, 0.58 to 0.92; p=0.007; for R0-1 mm and R0 mm: HR, 0.78; 95% CI, 0.65 to 0.94; p=0.010). Lastly, in three studies, the patients with distal pancreatectomy were included with the proportion of 15.3%-20.2% \[[@b23-crt-2016-336],[@b26-crt-2016-336],[@b27-crt-2016-336]\]. However, effect size was not significantly different by excluding these three studies (for R\>1 mm and R0-1 mm: HR, 0.71; 95% CI, 0.58 to 0.88; p=0.001; for R0-1 mm and R0 mm: HR, 0.84; 95% CI, 0.74 to 0.95; p=0.007).

Conclusion
==========

While existing controversy about R1 status in the resected pancreatic cancer, our meta-analysis suggests that patients with resection margin with 0-1 mm had reduced risk of death than those with involved margin status, and greater risk of death than those with \> 1 mm margin. Based on these result, stratification of patients based on margin distance with standardized pathological examination should be implicated in the future clinical trial of adjuvant therapy for pancreatic cancer.
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###### 

Characteristics of included studies

  Study                                                  Institution          Study period   No. (%)      Surgical treatment   T stage      N+ (%)                                              Adjuvant treatment                       
  ------------------------------------------------------ -------------------- -------------- ------------ -------------------- ------------ --------------------------------------------------- --------------------------------- ------ --------------------------------------------------
  Campbell et al. (2009) \[[@b16-crt-2016-336]\]         Liverpool (UK)       1997-2007      71 (43.6)    57 (35.0)            35 (21.5)    PPPD (90.2%), whipple (9.8%)                        T3/4 (85.3%)                      78.5   NA
  Chang et al. (2009) \[[@b23-crt-2016-336]\]            Sydney (Australia)   1990-2007      132 (36.2)   56 (15.3)            177 (48.5)   Whipple (80.8%), left side pancreatectomy (19.2%)   \> 2 cm (77.0%)                   59.5   Adjuvant CTx (26.3%), RT (5.8%)
  Janot et al. (2012) \[[@b24-crt-2016-336]\]            Bochum (Germany)     2007-2009      5 (8.1)      12 (19.4)            45 (72.6)    Whipple (11.3%), PPPD (69.3%), TP (19.4%)           T3/4 (91.9%), \> 2.5 cm (66.1%)   79.0   NA
  Thomay et al. (2012) \[[@b25-crt-2016-336]\]           Philadelphia (USA)   1991-2011      108 (36.4)   54 (18.2)            135 (45.5)   PD (100%)                                           NA                                NA     Neoadjuvant CRT (34%)
  Jamieson et al. (2013) \[[@b17-crt-2016-336]\]         Glasgow (UK)         1996-2011      111 (51.2)   46 (21.2)            60 (27.6)    PD (100%)                                           T3/4 (90.3%), \> 3 cm (50.7%)     80.2   Adjuvant therapy (47.0%), neoadjuvant CTx (0.9%)
  Sugiura et al. (2013) \[[@b26-crt-2016-336]\]          Sizuoka (Japan)      2002-2010      34 (16.3)    40 (19.2)            134 (64.4)   PD (78.8%), DP (20.2%), TP (1.0%)                   \> 3 cm (47.1%)                   69.2   Adjuvant CTx (84.6%), RT (11.5%)
  Konstantinidis et al. (2013) \[[@b27-crt-2016-336]\]   MGH (USA)            1993-2001      157 (31.7)   169 (34.1)           170 (34.3)   PD (83.1%), DP (15.3%), TP (1.4%)                   T3/4 (88.5%)                      70.0   NA
  Hashimoto et al. (2013) \[[@b28-crt-2016-336]\]        Wakayama (Japan)     2002-2012      30 (24.2)    38 (30.6)            56 (45.2)    PD (100%)                                           NA                                NA     NA

R0 mm, involved margin; R0-1 mm, margin clearance with ≤ 1 mm; R\>1 mm, margin with \> 1 mm; PPPD, pylorus preserving pancreaticocduodenectomy; NA, not applicable; CTx, chemotherapy; RT, radiotherapy; TP, total pancreatectomy; PD, pancreaticoduodenectomy; CRT, chemoradiation; DP, distal pancreatectomy.

###### 

Pathologic examination protocol

  Study                                                  Protocol                                          Evaluated margin
  ------------------------------------------------------ ------------------------------------------------- ----------------------------------------------------------------------
  Campbell et al. (2009) \[[@b16-crt-2016-336]\]         RCP \[[@b20-crt-2016-336]\]                       Pancreatic transection margin
                                                                                                           Medial (or superior mesenteric vessel) margin
                                                                                                           Posterior margin
                                                                                                           Proximal duodenal (or gastric) margin
                                                                                                           Distal duodenal margin
                                                                                                           Common bile duct margin
  Chang et al. (2009) \[[@b23-crt-2016-336]\]            Institutional                                     Pancreatic neck margin
                                                                                                           Portal vein/superior mesenteric vein margin
                                                                                                           Superior mesenteric artery/retroperitoneal (uncinate) margin
                                                                                                           Bile duct margin
                                                                                                           Proximal gastric/duodenal margin
                                                                                                           Distal duodenal margin
  Janot et al. (2012) \[[@b24-crt-2016-336]\]            Modified LEEPP \[[@b14-crt-2016-336]\]            Anterior margin
                                                                                                           Posterior margin (uncinate process)
                                                                                                           Superior mesenteric vein groove circumferential resection margin
                                                                                                           Transection margin (pancreatic neck, bile duct, and duodenum margin)
  Thomay et al. (2012) \[[@b25-crt-2016-336]\]           NA                                                NA
  Jamieson et al. (2013) \[[@b17-crt-2016-336]\]         RCP \[[@b20-crt-2016-336],[@b31-crt-2016-336]\]   Posterior margin
                                                                                                           Anterior margin
                                                                                                           Medial margin
                                                                                                           Pancreatic transection margin
  Sugiura et al. (2013) \[[@b26-crt-2016-336]\]          Japan Pancreas Society \[[@b30-crt-2016-336]\]    Pancreatic transection margin
                                                                                                           Superior mesenteric artery margin
                                                                                                           Posterior margin
                                                                                                           Proximal bile duct margin
  Konstantinidis et al. (2013) \[[@b27-crt-2016-336]\]   Staley et al. \[[@b29-crt-2016-336]\]             Common bile duct margin
                                                                                                           Pancreatic transection (neck) margin
                                                                                                           Posterior/retroperitoneal margin
                                                                                                           Uncinate (superior mesenteric artery) margin
  Hashimoto et al. (2013) \[[@b28-crt-2016-336]\]        NA                                                NA

RCP, Royal College of Pathologist; LEEPP, Leeds Pathology Protocol; NA, not applicable.

###### 

A summary of risk of bias assessment using the Risk of Bias Assessment Tool for Non-randomized Studies (RoBANS)

  Study                                                  Selection   Performance   Detection   Attrition   Reporting   
  ------------------------------------------------------ ----------- ------------- ----------- ----------- ----------- ---------
  Campbell et al. (2009) \[[@b16-crt-2016-336]\]         Low         Low           Low         Low         Unclear     Low
  Chang et al. (2009) \[[@b23-crt-2016-336]\]            Low         Low           Low         Low         Low         Low
  Janot et al. (2012) \[[@b24-crt-2016-336]\]            Low         Low           Low         Low         Unclear     Low
  Thomay et al. (2012) \[[@b25-crt-2016-336]\]           Low         High          Low         Low         Unclear     Unclear
  Jamieson et al. (2013) \[[@b17-crt-2016-336]\]         Low         Low           Low         Low         Low         Low
  Sugiura et al. (2013) \[[@b26-crt-2016-336]\]          Low         Low           Low         Low         Unclear     Low
  Konstantinidis et al. (2013) \[[@b27-crt-2016-336]\]   Low         High          Low         Low         Unclear     Low
  Hashimoto et al. (2013) \[[@b28-crt-2016-336]\]        Low         High          Low         Low         Unclear     Unclear
